stronger neominophagen c has been researched along with glycine in 18 studies
*Glycine: A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter. [MeSH]
*Glycine: A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter. [MeSH]
| Studies (stronger neominophagen c) | Trials (stronger neominophagen c) | Recent Studies (post-2010) (stronger neominophagen c) | Studies (glycine) | Trials (glycine) | Recent Studies (post-2010) (glycine) |
|---|---|---|---|---|---|
| 18 | 2 | 8 | 35,163 | 756 | 8,415 |
| Protein | Taxonomy | stronger neominophagen c (IC50) | glycine (IC50) |
|---|---|---|---|
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | 1.4852 | |
| Sodium- and chloride-dependent glycine transporter 1 | Homo sapiens (human) | 106 | |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | 0.3253 | |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 0.3253 | |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | 0.3253 | |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | 0.3253 | |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | 0.3253 | |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | 0.3253 | |
| Sodium- and chloride-dependent glycine transporter 2 | Homo sapiens (human) | 128 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (11.11) | 18.7374 |
| 1990's | 4 (22.22) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 8 (44.44) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Ishii, M; Miura, M; Miyazaki, Y; Takahashi, T; Toyota, T; Ueno, Y; Yamamoto, T | 1 |
| Abe, T; Fujimura, M; Matsuda, T; Nakatsumi, Y; Nomura, G | 1 |
| Shaikh, ZA; Vu, TT; Zaman, K | 1 |
| Aoki, M; Genka, I; Kikuchi, Y; Oka, S; Tachikawa, N; Teruya, K; Yamaguchi, M; Yamamoto, Y; Yasuoka, A; Yasuoka, C | 1 |
| Tarao, K | 1 |
| KASAI, K | 1 |
| AOCHI, Y; HIROSHIMA, Y; MIYAMOTO, A; YAMAMOTO, S | 1 |
| Bai, L; Bi, MR; Chen, LY; Ma, YJ; Wang, FX; Wang, Y; Yan, BZ; Yang, BS; Zhou, H | 1 |
| Ando, M; Gondo, T; Hidaka, I; Hino, K; Korenaga, M; Nishina, S; Okuda, M; Sakaida, I | 1 |
| Ding, JG; Fu, RQ; Hong, L; Sun, QF; Wang, JR; Wang, XF; Wu, JG; Xu, DZ; Xu, XJ; Yang, JX | 1 |
| Furutani, T; Gondo, T; Hidaka, I; Hino, K; Kawano, H; Korenaga, M; Nishina, S; Sakai, A; Sakaida, I; Shinozaki, A | 1 |
| Ikegami, T; Matsuzaki, Y; Saito, Y | 1 |
| Chang, Y; Zhang, L | 1 |
| Chen, J; Huang, Y; Li, J; Qin, T; Wang, J | 1 |
| Rino, Y; Yamamoto, N; Yukawa, N | 1 |
| Chen, G; Hu, XY; Liu, JL; Liu, XY; Luo, JX; Nie, HM; Wen, DC; Zhang, Y | 1 |
| Horikiri, T; Kaneko, Y; Kinoshita, A; Kurita, Y; Kuwano, K; Odashima, K; Saito, Z; Seki, A; Seki, Y; Takeda, H; Yoshii, Y | 1 |
| Ishizaki, J; Kitagawa, K; Nakano, C; Sai, Y; Suga, Y | 1 |
3 review(s) available for stronger neominophagen c and glycine
| Article | Year |
|---|---|
[Prevention of development of hepatocellular carcinoma from HCV-associated liver cirrhosis by multi-agents therapy including stronger-neo-minophagen C].
Topics: Anti-Inflammatory Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Cysteine; Drug Combinations; Drug Therapy, Combination; Drugs, Chinese Herbal; Glycine; Glycyrrhetinic Acid; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Risk; Treatment Outcome; Ursodeoxycholic Acid | 2001 |
[Efficacy and safety of Stronger Neo-Minophagen C for treatment of chronic hepatitis B: a meta-analysis of randomized controlled trials].
Topics: Cysteine; Drug Combinations; Glycine; Glycyrrhetinic Acid; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Randomized Controlled Trials as Topic | 2014 |
Does herbal medicine reduce the risk of hepatocellular carcinoma?
Topics: Animals; Anti-Inflammatory Agents; Benzimidazoles; Carcinoma, Hepatocellular; Clinical Trials as Topic; Cysteine; Drug Combinations; Drugs, Chinese Herbal; Fatty Liver; Fluorenes; Glycine; Glycyrrhetinic Acid; Glycyrrhizic Acid; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Neoplasms; Non-alcoholic Fatty Liver Disease; Phytotherapy; Plant Preparations; Sofosbuvir; Tablets | 2015 |
2 trial(s) available for stronger neominophagen c and glycine
| Article | Year |
|---|---|
Efficacy and safety of intravenous stronger neo-minophagen C and S-adenosyl-L-methionine in treatment of pregnant woman with chronic hepatitis B: a pilot study.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Cysteine; Demography; Drug Combinations; Drug Therapy, Combination; Embryonic Development; Female; Follow-Up Studies; Glycine; Glycyrrhetinic Acid; Health; Hepatitis B, Chronic; Humans; Infant, Newborn; Injections, Intravenous; Liver Function Tests; Pilot Projects; Pregnancy; S-Adenosylmethionine; Treatment Outcome | 2010 |
[Effect of decoction of turtle shell for anti-fibrosis combined with stronger neo-minophagen C on indices of hepatic fibrosis in chronic hepatitis B].
Topics: Adult; Aged; Alanine Transaminase; Animal Shells; Animals; Aspartate Aminotransferases; Cysteine; Drug Combinations; Drug Therapy, Combination; Female; gamma-Glutamyltransferase; Glycine; Glycyrrhetinic Acid; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Male; Medicine, Chinese Traditional; Middle Aged; Tissue Extracts; Treatment Outcome; Turtles | 2012 |
13 other study(ies) available for stronger neominophagen c and glycine
| Article | Year |
|---|---|
A case of drug-induced ductopenia resulting in fatal biliary cirrhosis.
Topics: Bile Duct Diseases; Bile Ducts, Intrahepatic; Cysteine; Drug Combinations; Female; Glycine; Glycyrrhetinic Acid; Glycyrrhizic Acid; Humans; Liver; Liver Cirrhosis, Biliary; Middle Aged; Rhinitis, Allergic, Seasonal | 1993 |
[Bronchial asthma due to Stronger Neo-Minophagen C].
Topics: Adult; Anti-Inflammatory Agents; Asthma; Cysteine; Drug Combinations; Female; Glycine; Glycyrrhetinic Acid; Humans; Steroids | 1998 |
Oxidative stress as a mechanism of chronic cadmium-induced hepatotoxicity and renal toxicity and protection by antioxidants.
Topics: Acetylcysteine; Alanine Transaminase; Amitrole; Animals; Anti-Inflammatory Agents; Antioxidants; Buthionine Sulfoximine; Cadmium; Cysteine; Drug Combinations; Enzyme Inhibitors; Female; Glutathione; Glycine; Glycyrrhetinic Acid; Kidney; L-Lactate Dehydrogenase; Lipid Peroxidation; Liver; Malondialdehyde; Oxidative Stress; Proteinuria; Rats; Rats, Sprague-Dawley; Steroids; Time Factors; Vitamin E | 1999 |
Mitigation of hepato-cellular injury caused by HAART with glycyrrhizin compound in patients co-infected with HIV and HCV.
Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Cysteine; Drug Combinations; Drug Therapy, Combination; Glycine; Glycyrrhetinic Acid; Hemophilia A; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1999 |
[On the effectiveness of stronger neo-minophagen C in epidemic keratoconjunctivitis].
Topics: Cysteine; Drug Combinations; Glycine; Glycyrrhetinic Acid; Humans; Keratoconjunctivitis | 1962 |
[On the antipyretic action of Stronger Neo-Minophagen C in a granuloma experiment].
Topics: Analgesics; Analgesics, Non-Narcotic; Antipyretics; Cysteine; Drug Combinations; Glycerol; Glycine; Glycyrrhetinic Acid; Granuloma; Humans | 1963 |
Protective effect and mechanism of stronger neo-minophagen C against fulminant hepatic failure.
Topics: Alanine Transaminase; Albumins; Animals; Apoptosis; Bilirubin; Caspase 3; Cysteine; Cytochromes c; Drug Combinations; Endothelin-1; Female; Glycine; Glycyrrhetinic Acid; Interleukin-6; Liver; Liver Failure, Acute; Mice; Microscopy, Electron; Tumor Necrosis Factor-alpha | 2007 |
Stronger Neo-Minophagen C, a glycyrrhizin-containing preparation, protects liver against carbon tetrachloride-induced oxidative stress in transgenic mice expressing the hepatitis C virus polyprotein.
Topics: Alanine Transaminase; Animals; Antioxidants; Carbon Tetrachloride; Chemical and Drug Induced Liver Injury; Cysteine; Cytochrome P-450 CYP2E1; Disease Models, Animal; Drug Combinations; Glutamate-Cysteine Ligase; Glutathione; Glycine; Glycyrrhetinic Acid; Hepacivirus; Liver; Liver Diseases; Male; Malondialdehyde; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mitochondria, Liver; Oxidative Stress; Polyproteins; RNA, Messenger; Viral Proteins | 2007 |
A glycyrrhizin-containing preparation reduces hepatic steatosis induced by hepatitis C virus protein and iron in mice.
Topics: Animals; Cysteine; DNA Primers; Dose-Response Relationship, Drug; Drug Combinations; Fatty Liver; Glycine; Glycyrrhetinic Acid; Glycyrrhizic Acid; Hepatitis C; Immunoblotting; Iron; Iron, Dietary; Liver; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microscopy, Electron, Transmission; Mitochondria; Oxidative Stress; Reactive Oxygen Species; Statistics, Nonparametric; Sterol Regulatory Element Binding Protein 1 | 2011 |
[Alternative therapies for hepatitis C: UDCA and SNMC].
Topics: Cysteine; Drug Combinations; Glycine; Glycyrrhetinic Acid; Hepatitis C, Chronic; Humans; Liver; Ursodeoxycholic Acid | 2011 |
Aqueous extract from Aconitum carmichaelii Debeaux reduces liver injury in rats via regulation of HMGB1/TLR4/NF-ΚB/caspase-3 and PCNA signaling pathways.
Topics: Aconitum; Animals; Caspase 3; Cysteine; Drug Combinations; Galactosamine; Glycine; Glycyrrhetinic Acid; HMGB1 Protein; Liver; Liver Diseases; Male; NF-kappa B; Plant Extracts; Proliferating Cell Nuclear Antigen; Rats; Rats, Wistar; Signal Transduction; Toll-Like Receptor 4 | 2016 |
Effectiveness of hepatoprotective drugs for anti-tuberculosis drug-induced hepatotoxicity: a retrospective analysis.
Topics: Adult; Aged; Alanine Transaminase; Antitubercular Agents; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Cysteine; Drug Combinations; Female; Glycine; Glycyrrhetinic Acid; Glycyrrhizic Acid; Humans; Liver; Male; Middle Aged; Retrospective Studies; Risk Factors; Tuberculosis; Ursodeoxycholic Acid; Young Adult | 2016 |
A Previously Unknown Drug-Drug Interaction Is Suspected in Delayed Elimination of Plasma Methotrexate in High-Dose Methotrexate Therapy.
Topics: Cysteine; Drug Combinations; Drug Interactions; Drug Monitoring; Female; Glycine; Glycyrrhetinic Acid; Humans; Leukemia; Logistic Models; Lymphoma; Male; Metabolic Clearance Rate; Methotrexate; Osteosarcoma; Retrospective Studies; Risk Factors; Vincristine | 2020 |